Authors
Latest:
Enterprise Leadership: Is Compliance Ripe for Disruption?Case study illustrates how compliance teams, in today’s climate, can foster innovation across an organization to help achieve corporate goals.
Latest:
Turning Safety and Regulatory to Business Driver with Natural Language ProcessingTo save time spent on manual reporting, pharmaceutical companies are turning to Natural Language Processing (NLP) which holds the combined potential for automating processes and enabling a deeper understanding of previously untapped data.
Latest:
Turning Safety and Regulatory to Business Driver with Natural Language ProcessingTo save time spent on manual reporting, pharmaceutical companies are turning to Natural Language Processing (NLP) which holds the combined potential for automating processes and enabling a deeper understanding of previously untapped data.
Latest:
How Oncologists are Coping with COVID-19Report highlights how oncology practices are becoming more virtual-oriented in light of the global pandemic.
Latest:
Strategic Realignment for a Better FutureIn adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
How to REVAMP Sales and Marketing During a Pandemic for Pharma with Value-Driven ApproachWhile the COVID-19 pandemic has put a halt to in-person selling for pharma companies, it has a created a new opportunity for reps to rethink and adapt to new strategies.
Latest:
How Oncologists Cope with COVID-19The COVID-19 pandemic has created challenges across the entirety of the medical landscape. Oncologists and hematologists are just a few of many healthcare providers (HCPs) that have had to adjust to these challenges on the fly.
Latest:
COVID-19: Expanding Remote Patient Services during LockdownStephanie Hill looks at the efforts made by patient solutions providers in the UK to build and support services outside the hospital environment during the pandemic.
Latest:
Patient Information Labeling and COVID-19In recent months, many pharma businesses have pivoted to entirely new product lines against a backdrop of unprecedented disruption to the supply chain. Gurdip Singh provide pointers to ensure companies are ready to adapt to change.
Latest:
Who Pays for Specialty Medicines?Providers and patients fish for that delicate balance between access and abandonment.
Latest:
Risk-Based Monitoring: From the Road Less Traveled to Productivity SuperhighwayThe latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
Latest:
One World, Many RegulationsThe ability to compete globally is essential to success in the pharmaceutical industry. The current trend is to establish joint ventures, outsource various stages of the development and production of a single pharma product, and purchase or start an indigenous business in other countries.
Latest:
Decision Making at Digital SpeedIn an era in which companies can forfeit $1 million each day they delay a product launch-and being second can mean failure-pharma executives are under pressure to make risk and opportunity decisions in less time than ever.
Latest:
GSK Invests in UK ManufacturingGlaxoSmithKline (GSK) will invest £200 million ($327 million) to expand its manufacturing facilities in Ware, Hertfordshire and Worthing, Sussex in the United Kingdom and establish a new manufacturing innovation facility.
Latest:
Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-TherapiesNew research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.
Latest:
The Truth About E-HealthThe returns are in, and they are not pretty. Janus Funds' billion-dollar investment in WebMD in 2000 now has a net value of roughly ten cents on the dollar, and many observers see WebMD as a winner in their space-whatever that space is now.
Latest:
Medical Affairs: From Info Gatekeeper to Legitimate Value DriverThe role of pharma medical affairs teams is taking on greater importance in the value chain.
Latest:
September 2016: Your Hub is Your Secret Weapon to Improve OutcomesHubs can be the secret weapon to providing customized solutions to the industry-wide challenge of improving patient outcomes.
Latest:
Market Access is Dead: Patient Access is the New Prescription for Healthcare MarketingParadigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. I
